106
Participants
Start Date
July 13, 2017
Primary Completion Date
June 10, 2019
Study Completion Date
July 20, 2019
Ribociclib
Ribociclib flat-fixed dose of 600 mg daily (three 200-mg capsules), days 1 to 21 of a 28-days cycle.
Letrozole 2.5mg
Daily continuous
Doxorubicin
60 mg/m2 as a continuous IV perfusion
Cyclophosphamide
600 MG/M2 in a 30 minutes IV infusion
Paclitaxel
80 mg/m2, in one hour IV infusion
Hospital Clinic de Barcelona, Barcelona
Hospital General de Catalunya, Barcelona
Hospital Universitari Vall d' Hebron, Barcelona
Institut Català d'Oncologia l'Hospitalet, Barcelona
Consorcio Hospitalario Provincial de Castellón, Castelló
Hospital San Pedro de Alcántara, Cáceres
Fundació Privada Hospital Asil de Granollers, Granollers
Centro Integral Oncologico Clara Campal, Madrid
Centro Oncológico MD Anderson International España, Madrid
Hospital Quirón Madrid, Madrid
Hospital Rey Juan Carlos, Madrid
Hospital Universitario 12 de octubre, Madrid
Hospital Universitario Fundación de Alcorcón, Madrid
Hospital Universitario Fundación Jiménez Díaz, Madrid
Hospital Universitari Son Espases, Palma
Complexo Hospitalario Universitario de Santiago, Santiago de Compostela
Hospital Virgen del Rocío, Seville
Hospital Virgen Macarena, Seville
Fundación Instituto Valenciano de Oncología, Valencia
Hospital Clínico Universitario de Valencia, Valencia
Hospital Universitari Arnau de Vilanova de València, Valencia
Collaborators (1)
Novartis
INDUSTRY
SOLTI Breast Cancer Research Group
OTHER